North America Cell And Gene Therapy Clinical Trials Market Size & Outlook
Related Markets
North America cell and gene therapy clinical trials market highlights
- The North America cell and gene therapy clinical trials market generated a revenue of USD 5,470.3 million in 2024.
- The market is expected to grow at a CAGR of 15% from 2025 to 2033.
- In terms of segment, phase iii was the largest revenue generating phase in 2024.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2025 to 2033.
North America data book summary
| Market revenue in 2024 | USD 5,470.3 million |
| Market revenue in 2033 | USD 19,233.9 million |
| Growth rate | 15% (CAGR from 2025 to 2033) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
Other key industry trends
- In terms of revenue, North America region accounted for 50.9% of the global cell and gene therapy clinical trials market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,515.7 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Clinical Trials Market Scope
Cell And Gene Therapy Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novotech | View profile | 1001-5000 | Sydney, New South Wales, Australia, Oceania | http://www.novotech-cro.com/ |
| Syneos Health | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | https://www.syneoshealth.com/ |
| Veristat | View profile | 501-1000 | London, England, United Kingdom, Europe | http://www.veristat.com |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | http://www.parexel.com |
| IQVIA Holdings Inc | View profile | 87000 | 2400 Ellis Road, Durham, NC, United States, 27703 | https://www.iqvia.com |
| Medpace Holdings Inc | View profile | 5800 | 5375 Medpace Way, Cincinnati, OH, United States, 45227 | https://www.medpace.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
North America cell and gene therapy clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 62.51% in 2024. Horizon Databook has segmented the North America cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2021 to 2033.
North America dominated the market with the largest market share in 2021. It accounted for 48.3% of the global cell and gene therapy clinical trials market owing to the huge R&D investments, the presence of global players, and their efforts to come up with newer patents.
Furthermore, the economic efficiency offered CROs rather than conducting an in-house study is expected to boost the outsourcing of cell and gene therapy clinical trials over the forecast period.
As per reported by PhRMA in 2019, there were 362 cell & gene therapies in clinical development in the U.S. representing a 20% increase from 2018. Also by the end of 2019, there were more than 1,000 cell & gene therapy clinical trials in process including 452 of gene-modified & cell-based immune-oncology, 352 gene therapies, 216 cell therapies & 46 tissue engineering.
Reasons to subscribe to North America cell and gene therapy clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America cell and gene therapy clinical trials market databook
-
Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America cell and gene therapy clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into North America cell and gene therapy clinical trials market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
North America cell and gene therapy clinical trials market size, by country, 2021-2033 (US$M)
North America Cell And Gene Therapy Clinical Trials Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
